In addition to helping make treatment decisions, COTA's real-world data platform can help oncologists understand and identify areas where there is treatment variability and help them work to contain cost in the long run, explained C.K. Wang, MD, senior medical director, COTA.
In addition to helping make treatment decisions, COTA's real-world data platform can help oncologists understand and identify areas where there is treatment variability and help them work to contain cost in the long run, explained C.K. Wang, MD, senior medical director, COTA.
Transcript
How does COTA’s real-world data platform help oncologists make decisions about their patients?
Oncologists today in coming up with a treatment plan, first of all, it’s a very complex process, but they resort to multiple sources. First and foremost is drug approvals. Secondly, the well-established treatment guidelines, and third, clinicians often draw from their own personal experience. That said, the patients that are sitting in from of them may not fit into any of those previous constructs. For example, today, only 3% to 5% of cancer patients participate in clinical trials, which ultimately lead to drug approvals. It is likely that patient sitting in front of the provider in that patient population was never represented or was not well-represented in that clinical trial.
So, what real-world data does and what COTA’s platform can do is to surface real-world treatment approaches for those patients, as well as real-world toxicities and outcomes. All of these different factors can help a clinician then ultimately make the best treatment decision for the patient. Now that said, real-world data and COTA’s platform is currently not being used at the point of care, but there are many exploratory discussions looking into this. I think that ultimately, how this can benefit providers, in addition to making treatment decisions, is to allow them insight into how they’ve treated these patients in the past, and therefore understand and identify areas where there is tremendous treatment variability and help them work to contain cost in the long run.
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
POSITIVE Trial Update on Patients With Breast Cancer Attempting Pregnancy
December 8th 2023At last year’s San Antonio Breast Cancer Symposium, POSITIVE trial primary outcome data were presented on breast cancer–free interval, with women who paused endocrine therapy to attempt pregnancy having a similarly small rate of recurrence vs external controls from the SOFT and TEXT trials: 8.9% vs 9.2%.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Refining Precision Prevention for Benign Breast Disease
December 7th 2023Many questions remain surrounding accurately classifying the risk of developing invasive breast cancer associated with the benign breast disease diagnoses of nonproliferative lesions and proliferative changes without atypia.
Read More
Exagamglogene Autotemcel Meets End Points in Severe Sickle Cell Disease, β-Thalassemia
December 7th 2023Two posters set to be presented at the 65th American Society of Hematology Annual Meeting & Exposition met their primary and secondary end points regarding exagamglogene autotemcel therapy for sickle cell disease and β-thalassemia.
Read More